Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

Stilla Technologies S.A.S.. (11/20/18). "Press Release: Stilla Technologies Completes €16 Million ($18 Million) Series A". Paris.

Organisations Organisation Stilla Technologies S.A.S.
  Organisation 2 Illumina Ventures
  Group Illumina (Group)
Products Product Naica System (digital PCR)
  Product 2 venture capital
Index terms Index term Stilla Technologies–SEVERAL: investment, 201811 financing round Series A €16m led by Illumina Ventures
  Index term 2 Stilla Technologies–Kurma: investment, 201811 financing round Series A totalling €16m incl co-investor Kurma Partners
Persons Person Dangla, Rémi (Stilla Technologies 201610 CEO + Founder)
  Person 2 Naclerio, Nicholas J. (Nick) (Illumina 201512 SVP Corp + Venture before Quanterix + ParAllele + Zymoyx + Motorola)
     


> Objective: financing to commercialize its novel digital PCR system and develop clinical applications.

> Illumina Ventures led the financing round


Stilla Technologies, the European provider of pioneering digital PCR solutions for high precision genetic analysis, announced today the successful completion of a Series A financing round of 16 million euros ($18 Million) led by Illumina Ventures, with participation fromKurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds & Idinvest Partners. As part of the financing, Nick Naclerio (Illumina Ventures), Philippe Peltier (Kurma Partners) and Philippe Chambon (LBO France) have joined the board of directors, replacing the seed investors.

Since 2016, Stilla Technologies has been providing research organizations specialized in molecular biology and genetic analysis with its Naica System, a ground-breaking digital PCR solution that enables scientists to detect and quantify DNA mutations with unrivalled precision.

“With our Naica System, researchers worldwide are building a new generation of high-precision genetic tests, in various fields of applications such as liquid biopsy tests for cancer diagnostics, pre-natal testing or GMO detection” commented Rémi Dangla, CEO and co-founder of Stilla Technologies.”The additional financing will enable Stilla to accelerate the sales of the Naica System, launch our 2nd generation solution, and begin clinically validating panels to be run on the system with an initial focus in the field of oncology.”

“We are very excited to be working with Stilla and such a deep syndicate of European investors added Nick Naclerio, Founding Partner of Illumina Ventures. “The Stilla team has done an amazing job developing and launching the Naica system in Europe and Asia with a very limited amount of seed financing. With these additional resources, we believe that Stilla Technologies can become a global leader in digital PCR and the lowest cost platform for liquid biopsies.”

Stilla Technologies will be presenting its latest products and developments in the field of digital PCR at the upcoming annual 4BIO Summit – Europe in Rotterdam, Netherlands on the 27th and 28th of November 2018.


About Stilla Technologies

Founded in 2013 at Ecole Polytechnique, Stilla Technologies is a Paris-based European Life Sciences company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas. Stilla actively advises and supports its customers worldwide through its dynamic and multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.

www.stillatechnologies.com


About Illumina Ventures

Illumina Ventures is an independently-managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. As an early-stage, valueadd investor, we help entrepreneurs develop breakthrough science and technologies into marketleading companies to transform healthcare. We focus on investment in life science tools, therapeutics, diagnostics, and personal wellness. www.illuminaventures.com


About LBO France

Since its inception in 1985, pioneer in the French Private Equity market, with €3.4 billion under management as of December 2017, LBO France is one of the largest private equity firms in France in the discounted market. LBO France, through its digital health funds, supports the growth of innovative SMEs in Digital Health and the Silver Economy. https://www.lbofrance.com


About Kurma Partners

Created in 2009, Kurma Partners is an European leading venture capital group specialized in Life Sciences and managing Kurma Biofund I, Kurma Biofund II and its accelerator fund, Kurma Diagnostics. The company has more than €250 million under management and develops an investment strategy supported by both the selection of the best investment opportunities in Europe and the development of a "proprietary" portfolio of companies in which Kurma steps in at creation stage. www.kurmapartners.com


About Idinvest

Idinvest Partners is a leading European mid-market private equity firm. With close to €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market corporate debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services. Founded in 1997 Idinvest Partners used to be an Allianz subsidiary until 2010, when it branched out as an independent firm. In January 2018, Idinvest Partners joined forces with Eurazeo to create a private equity leader in Europe and North America with €15bn under management. www.idinvestpartners.com


About BNP Paribas Développement

BNP Paribas Développement, a BNP Paribas Group subsidiary founded in 1988, invests its own capital directly in promising small and medium-sized enterprises and mid-cap companies. As a minority shareholder in these target companies, BNP Paribas Développement seeks to promote their growth and ensure their longer-term prosperity by facilitating ownership transfer. It manages a portfolio of 400 companies including 50 startups. www.bnpparibasdeveloppement.com ;


Contacts

Stilla Technologies
Marketing Manager
Sarah Jemai
sarah.jemai@stilla.fr

Alize RP
Press Relations France/EU
Aurore Gangloff
agangloff@alizerp.com
+33 (0)1 44 54 36 66

Seismic
Press Relations US
Eric Shubert
eric@teamseismic.com

   
Record changed: 2018-11-22

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top